• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴西对剑桥肺动脉高压结局评估(CAMPHOR)生活质量评估的改编与验证。

Adaptation and validation of the quality of life assessment of the Cambridge pulmonary hypertension outcome review (CAMPHOR) for Brazil.

作者信息

Corrêa Ricardo Amorim, Pereira Monica Corso, Bizzi Mariana Ferreira, de Oliveira Rafael W R, Rezende Camila Farnese, de Oliveira Bruna Cristina Marabita Tavares, Heaney Alice, McKenna Stephen P, Ribeiro-Oliveira Antonio

机构信息

Department of Internal Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.

Department of Internal Medicine, University of Campinas, Sao Paulo, Brazil.

出版信息

J Patient Rep Outcomes. 2020 Jun 5;4(1):43. doi: 10.1186/s41687-020-00209-6.

DOI:10.1186/s41687-020-00209-6
PMID:32504261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7275099/
Abstract

BACKGROUND

Pulmonary Hypertension (PH) impacts negatively on patients' health-related quality of life (HRQoL). The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) was the first PH-specific and validated instrument for use in different languages worldwide. This report describes the adaptation and psychometric validation of the CAMPHOR into Brazilian Portuguese language.

METHODS

The translation and validation process included a bilingual and lay panel translation; cognitive debriefing interviews; psychometric testing in two repeated times assessing internal consistency, reproducibility and validity of the questionnaire. The Nottingham Health Profile (NHP) questionnaire was used as a comparator to test for convergent validity.

RESULTS

The translation captured the same concepts as the English questionnaire and produced a comprehensive instrument in a Brazilian-Portuguese version expressing common, natural language. The psychometric evaluation involved 102 patients (48.8 ± 14.5 years, 80,4% female]. Cronbach's alpha coefficients were above 0.9 on all three CAMPHOR scales. There was excellent test-retest reliability (coefficients above 0.85 on all scales). CAMPHOR Symptoms scale and Activities scale correlated highly with Physical Mobility section and CAMPHOR QoL scale was strongly associated with the Emotional Reactions and Social Isolation sections of NHP. There was a significant association between gender and perceived general health (p < 0.05). There were significant differences in CAMPHOR scale scores between patients who differed according to their perceived disease severity and general health.

CONCLUSIONS

The present CAMPHOR version demonstrated good psychometric properties and provides a reliable instrument for assessing HRQL and QoL in Brazilian PH patients, addressing patients' perspective of their illness in a comprehensive way.

摘要

背景

肺动脉高压(PH)对患者的健康相关生活质量(HRQoL)产生负面影响。剑桥肺动脉高压结局评估(CAMPHOR)是首个针对肺动脉高压且在全球范围内得到验证的可用于不同语言的工具。本报告描述了将CAMPHOR改编并进行心理测量学验证以用于巴西葡萄牙语的过程。

方法

翻译和验证过程包括双语和非专业小组翻译;认知反馈访谈;分两次进行心理测量测试,以评估问卷的内部一致性、可重复性和有效性。使用诺丁汉健康状况问卷(NHP)作为对照来测试收敛效度。

结果

翻译后的问卷与英文问卷涵盖相同概念,并生成了一个用巴西葡萄牙语表达常见自然语言的综合工具。心理测量学评估涉及102名患者(年龄48.8±14.5岁,80.4%为女性)。CAMPHOR的所有三个量表的克朗巴哈系数均高于0.9。重测信度极佳(所有量表的系数均高于0.85)。CAMPHOR症状量表和活动量表与身体活动部分高度相关,CAMPHOR生活质量量表与NHP的情绪反应和社会隔离部分密切相关。性别与自我感知的总体健康状况之间存在显著关联(p<0.05)。根据自我感知的疾病严重程度和总体健康状况不同的患者,其CAMPHOR量表得分存在显著差异。

结论

目前的CAMPHOR版本显示出良好的心理测量学特性,并为评估巴西肺动脉高压患者的HRQL和QoL提供了一个可靠的工具,以全面的方式体现患者对自身疾病的看法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/799a/7275099/ccdf06301567/41687_2020_209_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/799a/7275099/d30b5093aa19/41687_2020_209_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/799a/7275099/ccdf06301567/41687_2020_209_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/799a/7275099/d30b5093aa19/41687_2020_209_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/799a/7275099/ccdf06301567/41687_2020_209_Fig2_HTML.jpg

相似文献

1
Adaptation and validation of the quality of life assessment of the Cambridge pulmonary hypertension outcome review (CAMPHOR) for Brazil.巴西对剑桥肺动脉高压结局评估(CAMPHOR)生活质量评估的改编与验证。
J Patient Rep Outcomes. 2020 Jun 5;4(1):43. doi: 10.1186/s41687-020-00209-6.
2
Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire.剑桥肺动脉高压结局评估(CAMPHOR)问卷的葡萄牙语验证
Health Qual Life Outcomes. 2016 Jul 26;14(1):110. doi: 10.1186/s12955-016-0513-8.
3
Adaptation and Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for Use in Spain.适用于西班牙的《剑桥肺动脉高压结局评估》(CAMPHOR)的改编与验证
Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):467-473. doi: 10.1016/j.rec.2016.11.007. Epub 2016 Dec 15.
4
Adaptation and validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Netherlands.剑桥肺动脉高压结局评估(CAMPHOR)在荷兰的适应性调整与验证
Neth Heart J. 2016 Jun;24(6):417-424. doi: 10.1007/s12471-016-0849-z.
5
The Polish adaptation of the CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR).波兰版剑桥肺高压预后评估(CAMPHOR)。
Cardiol J. 2020;27(5):608-615. doi: 10.5603/CJ.a2018.0119. Epub 2018 Oct 19.
6
The German adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).德国版剑桥肺高血压结局研究(CAMPHOR)。
Health Qual Life Outcomes. 2012 Sep 13;10:110. doi: 10.1186/1477-7525-10-110.
7
ADAPTATION AND VALIDATION OF THE CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR) FOR CROATIA.《剑桥肺动脉高压结局评估量表(CAMPHOR)》在克罗地亚的适应性调整与验证
Acta Clin Croat. 2019 Mar;58(1):3-12. doi: 10.20471/acc.2019.58.01.01.
8
Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian.将《剑桥肺动脉高压结局评估》(CAMPHOR)改编为加拿大法语版和加拿大英语版。
Can Respir J. 2008 Mar;15(2):77-83. doi: 10.1155/2008/767126.
9
Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden.瑞典剑桥肺高血压结局研究的改编和验证。
Scand J Public Health. 2012 Dec;40(8):777-83. doi: 10.1177/1403494812464445. Epub 2012 Oct 31.
10
Translation and validation of the greek Psoriatic Arthritis Quality of Life Scale.希腊银屑病关节炎生活质量量表的翻译与验证
Psychiatriki. 2017 Jul-Sep;28(3):219-225. doi: 10.22365/jpsych.2017.283.219.

引用本文的文献

1
The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.PlexiQoL,一种用于神经纤维瘤病 1 型相关丛状神经纤维瘤患者生存质量的患者报告结局测量量表:荷兰语版的翻译、文化调适及验证。
J Patient Rep Outcomes. 2024 Mar 18;8(1):33. doi: 10.1186/s41687-024-00714-y.
2
The effect of high blood pressure-health literacy, self-management behavior, self-efficacy and social support on the health-related quality of life of Kazakh hypertension patients in a low-income rural area of China: a structural equation model.高血压-健康素养、自我管理行为、自我效能感及社会支持对中国低收入农村地区哈萨克族高血压患者健康相关生活质量的影响:一项结构方程模型研究
BMC Public Health. 2021 Jun 10;21(1):1114. doi: 10.1186/s12889-021-11129-5.
3

本文引用的文献

1
Cross-cultural adaptation of the Cambridge Pulmonary Hypertension Outcome Review for use in patients with pulmonary hypertension in Colombia.跨文化适应的剑桥肺高血压结局研究在哥伦比亚肺高血压患者中的应用。
J Bras Pneumol. 2019 Jul 29;45(6):e20180332. doi: 10.1590/1806-3713/e20180332.
2
ADAPTATION AND VALIDATION OF THE CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR) FOR CROATIA.《剑桥肺动脉高压结局评估量表(CAMPHOR)》在克罗地亚的适应性调整与验证
Acta Clin Croat. 2019 Mar;58(1):3-12. doi: 10.20471/acc.2019.58.01.01.
3
Medium-term health-related quality of life in patients with pulmonary arterial hypertension treated with goal-oriented sequential combination therapy based on exercise capacity.
A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension.通过剑桥肺动脉高压结局评估所测量的特发性肺动脉高压患者的最小临床重要差异。
Pulm Circ. 2021 May 21;11(2):2045894021995055. doi: 10.1177/2045894021995055. eCollection 2021 Apr-Jun.
基于运动能力的目标导向序贯联合治疗对肺动脉高压患者的中期健康相关生活质量的影响。
Health Qual Life Outcomes. 2019 Jun 14;17(1):103. doi: 10.1186/s12955-019-1178-x.
4
The importance of patient perspectives in pulmonary hypertension.患者视角在肺动脉高压中的重要性。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01919-2018. Print 2019 Jan.
5
Risk stratification and medical therapy of pulmonary arterial hypertension.肺动脉高压的风险分层与药物治疗。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01889-2018. Print 2019 Jan.
6
Haemodynamic definitions and updated clinical classification of pulmonary hypertension.血流动力学定义和肺动脉高压的最新临床分类。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01913-2018. Print 2019 Jan.
7
Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.马昔腾坦改善肺动脉高压患者的健康相关生活质量:随机对照SERAPHIN试验的结果
Chest. 2017 Jan;151(1):106-118. doi: 10.1016/j.chest.2016.08.1473. Epub 2016 Sep 23.
8
Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire.剑桥肺动脉高压结局评估(CAMPHOR)问卷的葡萄牙语验证
Health Qual Life Outcomes. 2016 Jul 26;14(1):110. doi: 10.1186/s12955-016-0513-8.
9
Pulmonary arterial hypertension: the burden of disease and impact on quality of life.肺动脉高压:疾病负担及对生活质量的影响。
Eur Respir Rev. 2015 Dec;24(138):621-9. doi: 10.1183/16000617.0063-2015.
10
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015 ESC/ERS 肺动脉高压诊断与治疗指南:欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)肺动脉高压诊断与治疗工作组制定:该指南得到了欧洲儿科和先天性心脏病协会(AEPC)以及国际心肺移植学会(ISHLT)的认可。
Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29.